The Decline in Market Liquidity
While the Fed isn’t worried about the fall in market liquidity, experts argue that if investors make abrupt changes in their portfolios, the lack of liquidity could produce a crisis.
Read more...While the Fed isn’t worried about the fall in market liquidity, experts argue that if investors make abrupt changes in their portfolios, the lack of liquidity could produce a crisis.
Read more...Greece and its creditors have reached agreement on key terms for a so-called “third bailout”
Read more...A successful initiative in the UK to obtain more registration and publication of clinical trial data has had its US launch utterly ignored , not simply the mainstream media but also the logical suspects in the medical trade press and scholarly journals..
Read more...Oilfield services providers like Halliburton and Schlumberger are so desperate to keep the fracking party going that they are extending credit to already-levered frackers.
Read more...Pension consulting firm PCA tells some real howlers in trying to defend the failure of public pension funds like CalPERS to report the “carry fees” they pay.
Read more...Despite the 7% GDP growth published and hotly defended by the Chinese government, it is increasingly clear that the country is beset with a host of immense problems, after a debt-fueled binge of overbuilding and over-stimulating.
Read more...Yet again, HIllary Clinton tries to distance herself from her “sell out the middle class” policies, this time on “free trade”.
Read more...The Republican candidates for President all made shameless appeals for even more plutocracy, in particular preferential treatment for the rich.
Read more...If Greece decides to exit the euro and abrogate contracts, it is not likely to fare well in the tidal wave of lawsuits and arbitration cases that would ensue.
Read more...By challenging the private equity secrecy and fee-gouging regimes, a major Dutch pension fund shows how craven its US counterparts are.
Read more...Another example of the corruption of science: the press falls all over itself hyping Praluent, a new cholesterol-lowering drug with remarkably inconclusive clinical trial data behind it. As Roy Poses points out, “The clinical benefit of the drug was not evident in this trial.”
Read more...I felt I had not adequately commemorated the 70th anniversary of the bombing of Hiroshima and Nagasaki, and am putting up this offering to make up for that lapse.
Read more...